← Leaderboards
Rachel Beyer
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Autologous”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$46,791,890
- Mary M Horowitz · Medical College Of Wisconsin$38,654,527
- Louis J. Picker · Oregon Health And Science University$32,726,954
- David Wofsy · University Of California, San Francisco$31,423,453
- Douglas F Nixon · J. David Gladstone Institutes$28,670,832
Research focus
AutologousProductionVectorOperative Surgical ProceduresGene TherapyCellular TransductionCellsT-LymphocyteViral VectorRetroviral VectorVirusNeoantigensReagentIndividualized MedicineViralRetroviridaeGenerationsManufactureTumor-Infiltrating LymphocytesTumorProgramsMutationT-Cell ReceptorCore Facility
Grant awards (18)
QC and Release Testing of Vector and Cell Clinical Gene Therapy Products$1,154,517
ZIC · FY2025 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$1,026,237
ZIC · FY2025 · CA · contact PI
Use of lentivirus in individualized cell-gene therapy$384,839
ZIC · FY2025 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$1,131,975
ZIC · FY2024 · CA · contact PI
QC and Release Testing of Vector and Cell Clinical Gene Therapy Products$880,425
ZIC · FY2024 · CA · contact PI
Use of lentivirus in individualized cell-gene therapy$503,100
ZIC · FY2024 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$693,211
ZIC · FY2023 · CA · contact PI
QC and Release Testing of Clinical Vector and Cell Gene Therapy Products$693,211
ZIC · FY2023 · CA · contact PI
Use of lentivirus in individualized cell-gene therapy$346,606
ZIC · FY2023 · CA · contact PI
QC and Release Testing of Clinical Vector and Cell Gene Therapy Products$434,646
ZIC · FY2022 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$434,646
ZIC · FY2022 · CA · contact PI
Use of lentivirus in individualized cell-gene therapy$217,324
ZIC · FY2022 · CA · contact PI
QC and Release Testing of Clinical Vector and Cell Gene Therapy Products$462,714
ZIC · FY2021 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$462,714
ZIC · FY2021 · CA · contact PI
Characterization of lentivirus for use in individualized cell-gene therapy$231,357
ZIC · FY2021 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$1,380,777
ZIC · FY2020 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$730,187
ZIC · FY2019 · CA · contact PI
Clinical production of viral vectors for cancer gene therapy$823,336
ZIC · FY2018 · CA · contact PI